SHAREHOLDER ALERT: WeissLaw LLP Reminds XLRN, JMP, ECHO, and KDMN Shareholders About Its Ongoing Investigations

-

If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:

Joshua Rubin, Esq.
WeissLaw LLP
305 Broadway, 7 th Floor
New York , NY  10007
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

Acceleron Pharma Inc. (NASDAQ: XLRN)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Acceleron Pharma Inc. (NASDAQ: XLRN) in connection with the proposed acquisition of the Company by Merck & Co., Inc. ("Merck") (NYSE: MRK), via a tender offer.  Under the terms of the merger agreement, XLRN shareholders will receive $180.00 per share in cash for each share of XLRN common stock that they hold.  If you own XLRN shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/xlrn

JMP Group LLC (NYSE: JMP)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of JMP Group LLC (NYSE: JMP) in connection with the proposed acquisition of the company by Citizens Financial Group Inc.  Under the terms of the merger agreement, JMP shareholders will receive $7.50 per share in cash for each share of JMP common stock that they hold.  If you own JMP shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/jmp

Echo Global Logistics, Inc. (NASDAQ: ECHO)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Echo Global Logistics, Inc. (NASDAQ: ECHO) in connection with the proposed acquisition of the company by funds managed by The Jordan Company, L.P.  Under the terms of the merger agreement, ECHO shareholders will receive $48.25 per share in cash for each share of ECHO stock that they hold.  If you own ECHO shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/echo

Kadmon Holdings, Inc. (NASDAQ: KDMN)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Kadmon Holdings, Inc. (NASDAQ: KDMN) in connection with the proposed acquisition of the company by Sanofi ("Sanofi").  Under the terms of the merger agreement, the company's shareholders will receive $9.50 per share in cash for each share of KDMN stock that they hold.  If you own KDMN shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/kadmon-holdings-inc

View original content to download multimedia: https://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-reminds-xlrn-jmp-echo-and-kdmn-shareholders-about-its-ongoing-investigations-301395829.html

SOURCE WeissLaw LLP

News Provided by Canada Newswire via QuoteMedia

New Found Gold

New Found Gold Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
New Found Gold Corp. (TSXV:NFG)

New Found Gold

Emerging Canadian gold producer advancing high-grade assets in Newfoundland and Labrador

Emerging Canadian gold producer advancing high-grade assets in Newfoundland and Labrador Keep Reading...
InMed Announces Results of 2025 Annual General and Special Meeting

InMed Announces Results of 2025 Annual General and Special Meeting

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today confirmed that, at its annual general and special meeting of shareholders... Keep Reading...
InMed Provides Update on BayMedica Commercial Business

InMed Provides Update on BayMedica Commercial Business

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today released the following statement.Recently, H.R. 5371, the "Continuing... Keep Reading...
Thian Chew, CEO of Invion

Invion Advances Global Strategy With New Licencing Agreement

Invion (ASX:IVX) has taken a major step forward with a new global licencing agreement that streamlines its rights across key cancer and infectious disease programs. The move gives the company a clearer path to advance its Photosoft technology, expand market opportunities and strengthen... Keep Reading...
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs in 2025

The global pharmaceutical market is set to surpass a total value of US$1.75 trillion by the end of the decade, according to Evaluate Pharma.Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma... Keep Reading...
InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901

InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901

Data demonstrate a favorable bioavailability profile of INM-901 oral formulationData will support design and planning of first in human clinical trialsPreparing for pre-IND meeting with the FDA InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company... Keep Reading...
New Found Gold

New Found Gold Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Interactive Chart

Latest Press Releases

Related News